2015-03-09 |
1 |
Exhibit D - US 8,748,425 |
Exhibit A - US 7,030,149, # 2 Exhibit B - US 7,320,976, # 3 Exhibit C - US 7,642,258, # 4 Exhibit D -…
30 December 2016
2:15-cv-00347
830 Patent
Both
District Court, E.D. Texas
|
External link to document |
2015-04-06 |
14 |
|
.S. Patent Nos. 7,642,258 (“the ’258 patent”), 7,320,976 (“the ’976 patent”),
and the ’425 patent.
… United States Patent Nos. 7,030,149 (“the
’149 patent”), 7,320,976 (“the ’976 patent”), the 7,642,258…infringed U.S. Patent Nos.
7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not …latest of the expiration dates
of U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258.
…in
ANDA No. 91-087 infringed U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258.
Sandoz |
External link to document |
2015-08-13 |
28 |
|
0.5% timolol: U.S. Patent Nos. 7,030,149 (“the ’149 patent”), 7,320,976 (“the ’976 patent”),
the now-invalid…,463 (“the ’463 patent”), 7,642,258 (“the ’258 patent”), 8,133,890 (“the
’890 patent”), 8,354,409 (“the…Brim Tim I patents (the ’149, ’976, and ’258
patents), and the recently issued ’425 patent.
The… the ’890 patent and
the newly asserted ’425 patent.
Claim From ’890 Patent …Allergan’s main patent, upheld the non-
invalidity and infringement determination of one patent, and did not |
External link to document |
2015-08-31 |
37 |
|
of U.S. Patent No. 7,030,149, claim 1 of U.S. Patent No.
7,320,976, claims 1-6 of U.S. Patent No. 7,323,463… additional patent in this case, the ‘425
patent, which while similar to the ‘890 patent, likely presents…the then Orange Book listed patents for that drug, the
’149 and ’976 patents. Sandoz’s Paragraph IV letter… only that those patents were invalid
and did not separately assert that the patents were not infringed… all four patents-in-suit, relying on the stipulation of
infringement, and that the patents had not been |
External link to document |
2015-09-10 |
38 |
|
motion appeal.
Allergan listed U.S. Patent No. 8,748,425 in the Orange Book in July 2014, during … a branded manufacturer’s patents are invalid or not
infringed. The patent system is intended to encourage…earlier-filed actions involving the
same parties, the same patent family, and the same accused product), Sandoz asks… asks this Court to
resolve the parties’ patent dispute as quickly as possible. (See 2:09-cv-97 JRG (…in Brim Tim I, Sandoz
designed-around the only patent that the Federal Circuit found not invalid and |
External link to document |
2016-12-29 |
50 |
|
the patents-in-suit: U.S. Patent Nos.
7,030,149 (the “’149 patent”); 7,320,976 (the “’976 patent”); and…concerned three United States patents: the ’149, ’976, and
’425 patents. The patent claims asserted against…claim 4 of the ’149 patent,
claim 1 of the ’976 patent, and claims 1–8 of the ’425 patent (collectively, …apply to the ’976 patent.
C. The ’425 Patent
13. The ’425 patent issued on June … ’425, and ’890 patents, in addition to U.S. Patent Nos. 7,642,258
(the “’258 patent”) and 8,354,409 |
External link to document |
2017-12-21 |
61 |
USCA Opinion |
Hatch-Waxman Act, alleging infringement of
U.S. Patent Nos. 7,030,149, 7,320,976, and 8,748,425.
The U.S. District…4 of the ’149 patent,
claim 1 of the ’976 patent, and claims 1–8 of the ’425
patent protect Combigan… ’149 patent or
claim 1 of the ’976 patent, but does infringe claims 1–8 of
the ’425 patent.
… that the ’149, ’976, and ’425 patents
cover Combigan®. These patents share a common specifi-
cation…149 patent, see J.A. 350; (2) “a therapeutically
effective amount” in claim 1 of the ’976 patent, see |
External link to document |